All News
Filter News
Found 340 articles
-
Mersana Therapeutics Provides Statement About SVB
3/11/2023
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need, provided an update about its capital resources.
-
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 03, 2023
3/3/2023
Mersana Therapeutics, Inc. announced that on March 1, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of restricted stock unit awards to acquire an aggregate of 44,930 shares of its common stock, to four new employees whose employment commenced in February 2023.
-
Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
2/23/2023
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2022.
-
Mersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call on February 28, 2023
2/21/2023
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2022 on Tuesday, February 28, 2023.
-
Adaptimmune Announces Changes to Board of Directors
2/16/2023
Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in T-cell therapy to treat cancer, today announced that Kristen M. Hege, M.D. will join its board of directors.
-
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 03, 2023
2/3/2023
Mersana Therapeutics, Inc. announced that on February 1, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 42,000 shares of its common stock and restricted stock unit awards to acquire an aggregate of 97,665 shares of its common stock, to 10 new employees whose employment commenced in January 2023.
-
Mersana Therapeutics to Present at Upcoming Investor Conferences - February 02, 2023
2/2/2023
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need, announced that members of management will present at the following upcoming investor conferences:
-
Mersana Therapeutics Initiates Expansion Portion of UPGRADE-A Combination Clinical Trial in Platinum-Sensitive Ovarian Cancer
2/1/2023
Mersana Therapeutics, Inc. today announced that patient dosing is underway in the expansion portion of its UPGRADE-A clinical trial of UpRi in combination with carboplatin in platinum-sensitive ovarian cancer.
-
Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors
1/25/2023
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the initiation of patient dosing in its Phase 1 clinical trial of XMT-2056, the company’s lead Immunosynthen product candidate.
-
Adimab Provides 2022 Update on Clinical Pipeline
1/11/2023
Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that seven new partner programs entered clinical development in 2022, including programs by Biotheus, Dragonfly, Innovent, Surface Oncology, and a program with financial support from the Gates Foundation.
-
Adimab Provides Year-End Update on 2022 Partnership Activities
1/10/2023
Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that it entered into partnership agreements with 11 new companies in 2022.
-
In another early high-value deal, Amgen inked a licensing agreement with Synaffix for the development of next-generation antibody-drug conjugates.
-
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 06, 2023
1/6/2023
Mersana Therapeutics, Inc. announced that on January 3, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 25,575 shares of its common stock and restricted stock unit awards to acquire an aggregate of 26,700 shares of its common stock, to five new employees whose employment commenced in December 2022.
-
Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected Milestones
1/6/2023
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and announced strategic objectives and expected milestones for 2023.
-
Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug Conjugates
12/22/2022
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA, Darmstadt, Germany to discover novel Immunosynthen ADCs directed against up to two targets.
-
Merck KGaA, Darmstadt, Germany Announces Collaboration with Mersana Therapeutics to Develop Novel Immunostimulatory Antibody-Drug Conjugates
12/22/2022
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a research collaboration and commercial license agreement with Mersana Therapeutics, Inc., Cambridge, Massachusetts, USA to discover novel antibody-drug conjugates (ADCs) leveraging Mersana’s proprietary Immunosynthen STING-agonist ADC platform, directed against up to two targets.
-
European Commission Designates UpRi as an Orphan Medicinal Product for the Treatment of Ovarian Cancer
12/14/2022
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the European Commission (EC) has designated upifitamab rilsodotin (UpRi) as an orphan medicinal product for the treatment of ovarian cancer.
-
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 02, 2022
12/2/2022
Mersana Therapeutics, Inc. announced that on December 1, 2022, an authorized sub-committee of the Compensation Committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 16,425 shares of its common stock and restricted stock unit awards to acquire an aggregate of 14,175 shares of its common stock, to two new employees whose employment commenced in November 2022.
-
Generate Biomedicines Grows Leadership Team with Head of Vaccines and Infectious Disease Research and Senior Vice President of Technical Operations
11/22/2022
Generate Biomedicines today announced that Daria Hazuda, Ph.D., has been named Head of Vaccines and Infectious Disease Research and Lisa Wyman has been named Senior Vice President of Technical Operations.
-
Antibody-drug Conjugates (ADCs) Market Size 2022 to 2030 - Quantitative Research by QYResearch Medical
11/17/2022
The global antibody-drug conjugates (ADCs) market size was significantly large in 2020, and is expected to continue to register a rapidly inclining revenue CAGR between 2021 and 2030